Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
Cell Death Dis ; 2: e129, 2011 Mar 10.
Article in English | MEDLINE | ID: mdl-21390063

ABSTRACT

Safingol is a sphingolipid with promising anticancer potential, which is currently in phase I clinical trial. Yet, the underlying mechanisms of its action remain largely unknown. We reported here that safingol-induced primarily accidental necrotic cell death in MDA-MB-231 and HT-29 cells, as shown by the increase in the percentage of cells stained positive for 7-aminoactinomycin D, collapse of mitochondria membrane potential and depletion of intracellular ATP. Importantly, safingol treatment produced time- and concentration-dependent reactive oxygen species (ROS) generation. Autophagy was triggered following safingol treatment, as reflected by the formation of autophagosomes, acidic vacuoles, increased light chain 3-II and Atg biomarkers expression. Interestingly, scavenging ROS with N-acetyl-L-cysteine could prevent the autophagic features and reverse safingol-induced necrosis. Our data also suggested that autophagy was a cell repair mechanism, as suppression of autophagy by 3-methyladenine or bafilomycin A1 significantly augmented cell death on 2-5 µM safingol treatment. In addition, Bcl-xL and Bax might be involved in the regulation of safingol-induced autophagy. Finally, glucose uptake was shown to be inhibited by safingol treatment, which was associated with an increase in p-AMPK expression. Taken together, our data suggested that ROS was the mediator of safingol-induced cancer cell death, and autophagy is likely to be a mechanism triggered to repair damages from ROS generation on safingol treatment.


Subject(s)
Autophagy/drug effects , Cells/drug effects , Reactive Oxygen Species/metabolism , Sphingosine/analogs & derivatives , Cell Death/drug effects , Cell Line, Tumor , Cells/cytology , Cells/metabolism , HT29 Cells , Humans , Neoplasms/drug therapy , Neoplasms/metabolism , Neoplasms/physiopathology , Sphingosine/pharmacology
2.
Biosci Rep ; 22(2): 225-50, 2002 Apr.
Article in English | MEDLINE | ID: mdl-12428902

ABSTRACT

The presence of poly(ethylene glycol) (PEG) at the surface of a liposomal carrier has been clearly shown to extend the circulation lifetime of the vehicle. To this point, the extended circulation lifetime that the polymer affords has been attributed to the reduction or prevention of protein adsorption. However, there is little evidence that the presence of PEG at the surface of a vehicle actually reduces total serum protein binding. In this review we examine all aspects of PEG in order to gain a better understanding of how the polymer fulfills its biological role. The physical and chemical properties of the polymer are explored and compared to properties of other hydrophilic polymers. An evidence based assessment of several in vitro protein binding studies as well as in vivo pharmacokinetics studies involving PEG is included. The ability of PEG to prevent the self-aggregation of liposomes is considered as a possible means by which it extends circulation longevity. Also, a "dysopsonization" phenomenon where PEG actually promotes binding of certain proteins that then mask the vehicle is discussed.


Subject(s)
Liposomes/chemistry , Polyethylene Glycols/chemistry , Adsorption , Animals , Blood Proteins/metabolism , Half-Life , Humans , Hydrophobic and Hydrophilic Interactions , Liposomes/pharmacokinetics , Mice , Models, Chemical , Opsonin Proteins/metabolism , Pharmaceutical Vehicles , Polyethylene Glycols/pharmacokinetics , Protein Binding , Solubility , Structure-Activity Relationship , Surface Properties
SELECTION OF CITATIONS
SEARCH DETAIL
...